Company and Stock Identity

How AZmed Connects to the Public Market

Company structure
Private company
Market access
No current public listing was verified.
Research focus
Check the clearance against the finding you care about, one at a time. AZmed said on 15 September 2026 that AZchest covers pneumothorax, pleural effusion, consolidation and a raised cardiothoracic ratio, with lung nodules cleared separately in March 2025, so the suite is a stack of narrow permissions rather than one broad one. The company also calls AZtrauma the most extensively validated musculoskeletal X-ray AI in the world, which is its own claim, so ask for the studies and read who ran them.

No ownership change was found. Checked on 2026-10-10 against the company's own news page, where the 2026 items are hospital deployments and an FDA clearance rather than a sale or a listing.

Open the public company market data feed for the full directory, ownership relationships, stock identifiers, and dated snapshots.

First-Hand Company News

Latest Developments

... AZmed ... Company source

AZmed publishes five years of X-ray AI results from CHU de Reims

AZmed said on 7 October 2026 that the radiology department at CHU de Reims has used AZtrauma for fracture detection and AZchest for chest X-rays since 2021. The company cites a study in Pediatric Radiology covering 366 children under 18, which it says was run independently of AZmed and compared several fracture detection algorithms, reporting 93.6 percent specificity for Rayvolve and, for less experienced residents, sensitivity rising from 87.0 to 91.3 percent and specificity from 88.2 to 93.2 percent with AI help. AZmed separately cites a Radiography evaluation of 195,706 musculoskeletal X-rays, reporting an area under the curve of 0.983 for AZtrauma and 0.978 for AZchest.

Why it matters: The part worth reading twice is who ran the study. A hospital evaluation published in a journal and conducted without the vendor is stronger evidence than a company data sheet, and the Reims numbers show the biggest gain going to the least experienced readers. That is a useful way to think about where this kind of tool pays for itself. It is still one hospital and 366 children, so it describes that department rather than a promise for a busy adult trauma service.

... AZmed ... Company source

A Belgian hospital adds AZmed's measurement tool after four years of its fracture AI

AZmed said on 5 October 2026 that the radiology department at AZ Sint-Lucas in Belgium is adding AZmeasure alongside AZtrauma, which the hospital has used since 2022. The company reports 97.4 percent sensitivity and 96.4 percent specificity for AZtrauma across 195,706 X-rays, and a mean error of 1.8 degrees for angles and 1.1 millimetres for distances for AZmeasure, tested across 258,373 X-rays from 100 centres in 26 countries. AZmed also calls AZtrauma the most extensively validated musculoskeletal X-ray AI in the world, which is the company's own description.

Why it matters: An existing customer widening its contract is the clearest commercial signal in imaging AI, because the department has already lived with the false positives. Automated measurement is also a different job from fracture detection: it saves a radiologist time on angles and distances rather than catching something missed, so it is judged on agreement with a human, not on sensitivity. The validation counts here are the company's, and a number of scans is not the same as a number of independent studies.

... AZmed ... Company source

AZmed gets a sixth FDA clearance, adding four chest X-ray findings

AZmed said on 15 September 2026 that it received its sixth FDA clearance, covering AZchest for detecting and locating pneumothorax, pleural effusion, consolidation and an increased cardiothoracic ratio on frontal chest radiographs. With lung nodule detection cleared in March 2025, the company says AZchest now covers five findings per image and the wider Rayvolve suite covers eight FDA-cleared findings across musculoskeletal and chest X-rays.

Why it matters: Four findings on one image in a single clearance is a real widening, because each one would otherwise be a separate purchase, a separate integration and a separate set of alerts. A clearance says the FDA accepted the submission for those findings, so the useful comparison between vendors is the finding list and the scan type, not the clearance count. An increased cardiothoracic ratio is also a measurement rather than a diagnosis, and a buyer should know which of the four will actually change a report.

See company developments across the healthcare AI market.

Careers and Qualifications

What to Know Before Applying

Work areas: The careers page carries no open roles at the moment and asks people to send a resume with a note on how they would contribute. It says the company wants people interested in radiology AI who are comfortable in a startup.

Qualification signal: AZmed sells the same product into several national health systems, so people who have handled European and United States regulatory paperwork, or who have installed imaging AI in a hospital, matter more here than people who have only trained models.

Check current roles at AZmed. A careers page is the source of record for openings. This profile does not claim a role is open unless the company lists it now.

Related Healthcare AI Roles

Training to Compare

Buyer Snapshot

Best-fit buyer
Radiology leadership, pathology leadership, clinical informatics, imaging IT, patient safety, and procurement
Primary use case
Triage studies, flag findings, support image interpretation, and coordinate time-sensitive care
Typical deployment
Usually integrated with PACS, RIS, worklists, or digital pathology systems and monitored inside the clinical workflow

Evidence questions

  • Was the tool tested prospectively and independently on comparable equipment and patients?
  • What are sensitivity, specificity, false positive workload, and time-to-action effects?
  • How does performance vary by site, scanner, demographic subgroup, and disease prevalence?

Regulatory and workflow questions

  • Which FDA authorization covers the exact product version, modality, and intended use?
  • Who retains final clinical responsibility and how is disagreement with the AI handled?
  • What post-deployment monitoring and material update notification does the vendor provide?

Data and contract questions

  • Where are images and derived data processed and retained?
  • Which PACS, RIS, pathology, and EHR integrations are supported in production?
  • Can data be used for model improvement, and what controls govern secondary use?

Evidence and Regulation

FDA Clearances on Record

AZmed appears on 5 cleared products in the federal 510(k) record, across 2 device types.

A clearance means the FDA agreed the product is close enough to something already on the market to be sold for that use. It is not a finding that the product helps patients, and it is not a ranking against anything else on this page. A company is linked to an FDA clearance only when the 510(k) applicant name on the government record is confirmed by hand to be that same company, including former corporate names. Name similarity alone is never enough, and rejected matches are listed below with the reason.

What the Published Research Says About This Work

Independent studies on the work itself help separate category evidence from one company's claims.

First-Hand Sources